Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
LENALIDOMIDE LRX; LENALIDOMIDE LU (Luminarie Pty Ltd)
Product name
LENALIDOMIDE LRX; LENALIDOMIDE LU
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
156 (255 working days)
Active ingredients
lenalidomide
Registration type
New generic medicine
Indication
Multiple Myeloma (MM)
LENALIDOMIDE LRX; LENALIDOMIDE LU (capsule) is indicated for the treatment of multiple myeloma.
Myelodysplastic Syndromes (MDS)
Lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Mantle Cell Lymphoma (MCL)
Lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.